Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

BofA Raises JNJ Target to $278 Amid Strong Icotyde Projections

Guavy AI Editorial Team
Instruments
JNJ
Share

Johnson & Johnson's (JNJ) stock has fallen 1.28% to EUR 227.88 on October 2, 2026, at Lang & Schwarz, following a price target revision by Bank of America (BofA). BofA raised its target from USD 263 to USD 278, while maintaining a Neutral rating.

The increase in the price target is based on Icotyde, Johnson & Johnson's oral psoriasis treatment. BofA has increased its peak sales forecast for Icotyde to USD 4.5 billion from USD 2.4 billion and expects it to capture an 18% share of new advanced-treatment starts.

The upgrade is measured rather than aggressive, with BofA projecting third-quarter 2026 sales of USD 25.5 billion but lower earnings per share of USD 2.53 due to research costs tied to recent deals.

More on Stocks

Stocks 2m ago

Kahne Revs Engine, Returns to NASCAR for Truck Series Ride

Stocks 5m ago

IBM Expands AI Platform to Secure Environments Amid Share Price Concerns

Stocks 14m ago

Fitzpatrick's Return Brings New Questions for Jets' Secondary

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy